Important statistical considerations in the evaluation of post‐market studies to assess whether opioids with abuse‐deterrent properties result in reduced abuse in the community

• Kunthel ByUnited States Food and Drug Administration
• Jana McAninchUnited States Food and Drug Administration
• Stephine KeetonUnited States Food and Drug Administration
• Alex M. SecoraUnited States Food and Drug Administration
• Cynthia J. KornegayUnited States Food and Drug Administration
• Catherine S. HwangUnited States Food and Drug Administration
• Thomas LyUnited States Food and Drug Administration
• Mark S LevensonUnited States Food and Drug Administration